REG - Arecor Therapeutics - Arecor granted key European patent

Arecor TherapeuticsAnnouncement

18/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240118:nRSR0611Aa&default-theme=true

RNS Number : 0611A  Arecor Therapeutics PLC  18 January 2024

 

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR GRANTED KEY EUROPEAN PATENT EXTENDING PROTECTION FOR INSULIN PRODUCTS,
AT278 AND AT247

 

Cambridge, UK, 18 January 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
is pleased to announce that the European Patent Office has granted a patent
(EP3618840) protecting novel formulations of the Group's proprietary insulin
products, AT278 and AT247. The European patent adds to a comprehensive global
intellectual property (IP) portfolio protecting the Group's novel insulin
products and follows additional patents of similar scope recently granted in
Australia, India and Mexico.

 

Jan Jezek, Chief Scientific Officer at Arecor, commented: "We continue to
build a strong intellectual property portfolio in key markets for our
ultra-fast acting insulin products, AT278 and AT247, which provide the Group
significant growth potential in a multi-billion dollar market driven by the
need for tighter glucose control and the rise of innovative delivery devices
and digital technologies. AT278, our 'disrupter insulin' with its high
concentration and ultra-rapid profile has the potential to be the gold
standard insulin for the growing population of people with high daily insulin
needs and an essential component to enable patch pump miniaturisation and
extended wear-time. Further data to support its profile are expected in H1
2024 from the Group's clinical trial in a type 2 diabetes population."

 

Arecor has built a comprehensive IP portfolio protecting the Group's
Arestat™ technology platform and proprietary pipeline products. The
portfolio, which comprises 36 patent families and >90 granted patents in
Europe, the US and in other key territories, includes several patent families
providing robust IP protection of the Group's proprietary insulin products
until at least 2037.

 

 

-ENDS-

 

 

 

 

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:sarah.howell@arecor.com)

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville      Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSFWFWWELSEFF